Kiadis Pharma organizes a Satellite Symposium on March 30, 2014 at the 40th Annual Meeting of the European Society for Blood and Marrow Transplantation

Amsterdam, The Netherlands, March 24, 2014 – Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing T-cell immunotherapy treatments for blood cancers, today announces that it will organize a satellite symposium on March 30, 2014 at the 40th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) in Milan, Italy.
The satellite symposium hosted by Kiadis Pharma is entitled: “Effective T-cell immunotherapy with ATIR™ after haploidentical HSCT: Excellent OS with low GvHD” and will take place on Sunday March 30 from 16.00-18.00 CET in Room Space 4. The event will be chaired by Dr. Armand Keating, Professor of Medicine at the University of Toronto, Canada. Dr. Keating is past president of the American Society of Hematology (ASH) and the American Society for Blood and Marrow Transplantation (ASBMT). The speakers are respected key opinion leaders in the field of haploidentical stem cell transplantation and selective photodepletion: Professor Irwin Walker (Hamilton, Canada), Professor Stephan Mielke (Würzburg, Germany), Professor Denis-Claude Roy (Montreal, Canada), Dr. Robert Preti (Allendale, USA) and Professor John Barrett (Bethesda, USA). The program includes an overview of current challenges of alternative donor transplantations, how selective photodepletion can overcome these challenges, and what the potential of ATIR™ is in relation to alternative transplantation strategies using the preliminary results of the ongoing Phase II clinical study.
Additionally, the application of Quality by Design during process development of ATIR™ will be discussed, and how this resulted in stable and robust ATIR™ manufacturing.

Leave a comment

Your email address will not be published.